Sun Pharmaceutical Industries SUNPHARMA.NS
Sun Pharmaceutical Industries is an Indian pharmaceutical company that develops, manufactures, and markets branded and generic drugs, with a growing focus on specialty products in dermatology, ophthalmology, and oncology, sold primarily in India and the United States. Sun Pharma shows solid financial health (net cash, DN/EBITDA -1.74) and 27.4% earnings growth, but its valuation is demanding (PER 36.52) and the expansion of Trump's MFN drug pricing program in the US adds regulatory pressure on its key market.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Sun Pharmaceutical Industries is an Indian pharmaceutical company that develops, manufactures, and markets branded and generic drugs, with a growing focus on specialty products in dermatology, ophthalmology, and oncology, sold primarily in India and the United States. Sun Pharma shows solid financial health (net cash, DN/EBITDA -1.74) and 27.4% earnings growth, but its valuation is demanding (PER 36.52) and the expansion of Trump's MFN drug pricing program in the US adds regulatory pressure on its key market.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.6 |
| Quality / Moat | 8.0 |
| Valuation | 3.3 |
| Growth | 7.2 |
| Dividend | 5.3 |
| Momentum | 6.1 |
| Risk & Context | 6.4 |
OVERALL SCORE: 6.4/10
Context and risks
Material regulatory risk: the expansion of Trump's MFN drug pricing program directly affects the US market, key for Sun Pharma. Pricing pressure could compress margins in its generics and specialty portfolio.
News considered in the analysis
- Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President — La expansión del programa MFN de precios de medicamentos de Trump añade presión regulatoria directa sobre los precios en EE. UU., mercado clave para Sun Pharma.
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers — La inclusión de farmacéuticas medianas amplía el alcance del programa, afectando potencialmente a la cartera de genéricos y especialidad de Sun Pharma en EE. UU.
- Mid-cap biotechs join Trump’s latest round of drug pricing deals — La participación de biotechs de mediana capitalización indica que la presión sobre precios se extiende más allá de las grandes farmacéuticas, afectando a todo el sector.
- Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs — Análisis genérico sobre ETFs, sin información específica sobre Sun Pharma.
- Trump lines up MFN deals with nine mid-size pharmas on drug pricing push — Confirmación de la expansión del programa MFN, lo que aumenta el riesgo regulatorio para el segmento de genéricos en EE. UU.
Verdict: Hold; regulatory pressure on US drug pricing and demanding valuation limit near-term upside.
Main risk: The expansion of Trump's MFN drug pricing program in the US, which could compress margins and growth in its most important market.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →